I-125 versus Pd-103 for low-risk prostate cancer: Long-term morbidity outcomes from a prospective randomized multicenter controlled trial

Cancer Journal

Volumn 11, Issue 5, 2005, Pages 385-389

  Herstein, Andrew ^a   Wallner, Kent ^a,d,f   Merrick, Gregory ^a,e   Mitsuyama, Hiroki ^a,b,c   Armstrong, Julius ^a,b,c   True, Lawrence ^a,c   Cavanagh, William ^a,b,c   Butler, Wayne ^a,e  

^a University of Washington ^*

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e WHEELING HOSPITAL   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Brachytherapy; Prostatic carcinoma

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE 125; PALLADIUM 103;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSIMETRY; DRUG HALF LIFE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSTRUCTION; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE;

EID: 28444485693     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200509000-00005     Document Type: Article

References (14)

1. Ling CC. Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992;23:81-87.
2. Wallner K, Merrick G, True L et al. 1521 versus 103pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 2003;57:1297-1303.
3. Wallner K, Merrick G, True L et al. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002;8:67-73.
4. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Tech Urol 2000;6:78-84.
5. Mueller A, Wallner K, Corriveau J et al. A reappraisal of local anesthesia for prostate brachytherapy Radiother Oncol 2003;67:309:312.
6. Barry MJ, Fowler FJ, O'Leary MP et al. The American Urologic Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-1557.
7. Hilts M, Spandinger I, Keyes M. Comparison of methods for calculating rectal dose after (125)I prostate brachytherapy implants. Int J Radiat Oncol Biol Phys 2002;53:775-785.
8. Snyder KM, Stock RG, Hong SM et al. Defining the risk of developing grade 2 proctitis following 1251 prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50:335-341.
9. Mueller A, Wallner K, Merrick G et al. Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. Int J Radiat Oncol Biol Phys 2004;59:1047-1052.
10. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang X, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45:59-67.
11. Merrick GS, Butler WM, Wallner KE et al. Prophylactive versus therapeutic alpha-blockers after permanent prostate brachytherapy Urology 2002;60:650-655.
12. McElveen TL, Waterman FM, Kim H et al. Factors predicting for urinary incontinence after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004;59:1395-1404.
13. Tran A, Wallner K, Merrick G et al. Rectal fistulas following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;63:150-151.
14. Peschel RE, Colberg JW, Chen Z et al. Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications. Cancer J 2004;10:170-174.